LivemintGSK share price: Heart drug fails late-stage trialiNVEZZiNVEZZ.com, Tuesday, May 13: GlaxoSmithKline Plc (LON:GSK) has said that a drug failed to reduce heart attacks or other major events in patients with acute coronary syndrome in a late-stage trial. The result came after the drug, called darapladib, failed in …Glaxo Says Phase III Study of Heart Drug Fails to Hit TargetWall Street JournalGlaxoSmithKline Heart Disease Treatment Fails Late Stage TrialLondon South EastGSK study of coronary heart disease treatment fails to meet objectivesIFA MagazineThe Standard Digital Newsall 16 news articles …Read Full Story
GSK share price: Heart drug fails late-stage trial - iNVEZZ
Real Estate of Cebu
